Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Prostate Cancer

  Free Subscription

Articles published in Urol Int

Retrieve available abstracts of 59 articles:
HTML format

Single Articles

    March 2022
  1. WU J, Wei Y, Li T, Lin L, et al
    DNA Methylation-Mediated Lowly Expressed AOX1 Promotes Cell Migration and Invasion of Prostate Cancer.
    Urol Int. 2022 Mar 30:1-9. doi: 10.1159/000522634.
    PubMed     Abstract available

  2. MAKINO K, Sato Y, Takenaka R, Yamashita H, et al
    Cumulative Incidence and Clinical Risk Factors of Radiation Cystitis after Radiotherapy for Prostate Cancer.
    Urol Int. 2022 Mar 15:1-7. doi: 10.1159/000521723.
    PubMed     Abstract available

  3. HIGASHIYAMA S, Yoshida A, Kawabe J
    Predicting the Prognosis of Prostate Cancer Bone Metastasis Using the Bone Scan Index and Hot Spots Calculated Using VSBONE Bone Scan Index from Tc-99m-Hydroxymethylene Diphosphonate Bone Scintigraphy.
    Urol Int. 2022 Mar 4:1-7. doi: 10.1159/000522046.
    PubMed     Abstract available

    February 2022
  4. JIN C, Bian Z, Mo F, Zhu C, et al
    Establishment and Validation of Coagulation Factor-Based Nomogram for Predicting the Recurrence-Free Survival of Prostate Cancer.
    Urol Int. 2022 Feb 18:1-9. doi: 10.1159/000519329.
    PubMed     Abstract available

  5. SOKMEN BK, Sokmen D, Comez YI, Eksi M, et al
    Prediction of Prostate Cancer Aggressiveness Using a Novel Multiparametric Magnetic Resonance Imaging Parameter: Tumor Heterogeneity Index.
    Urol Int. 2022 Feb 11:1-8. doi: 10.1159/000521606.
    PubMed     Abstract available

  6. BORKOWETZ A, Blana A, Bohmer D, Cash H, et al
    German S3 Evidence-Based Guidelines on Focal Therapy in Localized Prostate Cancer: The First Evidence-Based Guidelines on Focal Therapy.
    Urol Int. 2022 Feb 10:1-9. doi: 10.1159/000521882.
    PubMed     Abstract available

  7. CAFUTA B, Distler FA, Wagner A, Pahernik S, et al
    Salvage Radiotherapy for Recurrent Prostate Cancer after High-Intensity Focused Ultrasound Therapy: Quality of Life and Functional Outcome.
    Urol Int. 2022 Feb 1:1-6. doi: 10.1159/000521660.
    PubMed     Abstract available

    January 2022
  8. PORCARO AB, Panunzio A, Tafuri A, Cerrato C, et al
    The Influence of Endogenous Testosterone Density on Unfavorable Disease and Tumor Load at Final Pathology in Intermediate-Risk Prostate Cancer: Results in 338 Patients Treated with Radical Prostatectomy and Extended Pelvic Lymph Node Dissection.
    Urol Int. 2022 Jan 26:1-12. doi: 10.1159/000521260.
    PubMed     Abstract available

  9. HARLAND N, Russo GI, Kaufmann S, Amend B, et al
    Robotic Transrectal Computed Tomographic Ultrasound with Artificial Neural Network Analysis: First Validation and Comparison with MRI-Guided Biopsies and Radical Prostatectomy.
    Urol Int. 2022;106:90-96.
    PubMed     Abstract available

  10. WETTERAUER C, Federer-Gsponer JR, Leboutte FDJP, Mona R, et al
    Indication for Active Surveillance in the Era of MRI-Targeted Prostate Biopsies.
    Urol Int. 2022;106:83-89.
    PubMed     Abstract available

  11. HAEUSER L, Reese SW, Paciotti M, Noldus J, et al
    Surgical Complications Requiring Intervention in Open versus Minimally Invasive Radical Prostatectomy.
    Urol Int. 2022;106:51-55.
    PubMed     Abstract available

  12. PFISTER D, Nestler T, Hartmann F, Haidl F, et al
    Feasibility and Oncologic Outcome of Salvage Surgery in Isolated Seminal Vesicle Remnants after Radical Prostatectomy.
    Urol Int. 2022;106:44-50.
    PubMed     Abstract available

    December 2021
  13. CROCEROSSA F, Carbonara U, Parekh J, Urdaneta A, et al
    PSA and PSA Kinetics as Predictors for 18F-Fluciclovine PET/CT Positivity in Biochemically Recurrent Prostate Cancer.
    Urol Int. 2021 Dec 21:1-8. doi: 10.1159/000520684.
    PubMed     Abstract available

  14. BERG S, Tully KH, von Landenberg N, Bahlburg H, et al
    How Many Cores Should Be Sampled during Systematic Prostate Biopsy in Case of Negative Multiparametric Magnetic Resonance Imaging? Analysis of 274 Men with Clinical Suspicion of Prostate Cancer.
    Urol Int. 2021 Dec 20:1-6. doi: 10.1159/000520598.
    PubMed     Abstract available

    November 2021
  15. FLEGAR L, Baunacke M, Buerk BT, Proschmann R, et al
    Decision Regret and Quality of Life after Focal Therapy with Vascular-Targeted Photodynamic Therapy (TOOKAD(R)) for Localized Prostate Cancer.
    Urol Int. 2021 Nov 23:1-6. doi: 10.1159/000520084.
    PubMed     Abstract available

  16. VESTRIS PG, Giwerc A, Hennequin C, Goujon A, et al
    Operative and Midterm Oncological Outcome of Focal Salvage Cryotherapy for Localized Prostate Cancer.
    Urol Int. 2021 Nov 15:1-6. doi: 10.1159/000518980.
    PubMed     Abstract available

    October 2021
  17. CETIN B, Wabl CA, Gumusay O
    Optimal Treatment for Patients with Oligometastatic Prostate Cancer.
    Urol Int. 2021 Oct 26:1-10. doi: 10.1159/000519386.
    PubMed     Abstract available

  18. GUO Y, Tian Y, Deng Y, Lu C, et al
    Diagnostic Performance of [18F]-Labeled PET/CT Tracers for Lymph Node/Bone Metastasis and Biochemical Recurrence Detection in Advanced Prostate Cancer: A Meta-Analysis.
    Urol Int. 2021 Oct 13:1-19. doi: 10.1159/000518478.
    PubMed     Abstract available

    September 2021
  19. LI Y, Cheng X, Zhu JL, Luo WW, et al
    Effect of Statins on the Risk of Different Stages of Prostate Cancer: A Meta-Analysis.
    Urol Int. 2021 Sep 8:1-9. doi: 10.1159/000518164.
    PubMed     Abstract available

    August 2021
  20. SONG P, Shu M, Yang L, Di X, et al
    The Prognosis of Radical Prostatectomy, External Beam Radiotherapy plus Brachytherapy, and External Beam Radiotherapy Alone for Patients above 70 Years with Very High-Risk Prostate Cancer: A Population-Matched Study.
    Urol Int. 2021 Aug 26:1-9. doi: 10.1159/000518113.
    PubMed     Abstract available

  21. PETERS R, Stephan C, Jung K, Lein M, et al
    Comparison of PHI and PHI Density for Prostate Cancer Detection in a Large Retrospective Caucasian Cohort.
    Urol Int. 2021 Aug 25:1-6. doi: 10.1159/000517891.
    PubMed     Abstract available

    July 2021
  22. TIAN B, Chunxiang E, Xiang Y, Teng P, et al
    Long Noncoding RNA LIPE-AS1 Drives Prostate Cancer Progression by Functioning as a Competing Endogenous RNA for microRNA-654-3p and Thereby Upregulating Hepatoma-Derived Growth Factor.
    Urol Int. 2021 Jul 7:1-16. doi: 10.1159/000516676.
    PubMed     Abstract available

    June 2021
  23. FERRO M, Terracciano D, Musi G, de Cobelli O, et al
    Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies.
    Urol Int. 2021 Jun 24:1-8. doi: 10.1159/000516680.
    PubMed     Abstract available

    May 2021
  24. KOPP D, Kopp J, Bernhardt E, Manka L, et al
    68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer.
    Urol Int. 2021 May 7:1-7. doi: 10.1159/000515651.
    PubMed     Abstract available

  25. PORCARO AB, Siracusano S, Amigoni N, Tafuri A, et al
    The Influence of Endogenous Testosterone on Incidental Prostate Cancer after Transurethral Prostate Resection.
    Urol Int. 2021 May 7:1-9. doi: 10.1159/000514391.
    PubMed     Abstract available

  26. CELIK S, Kizilay F, Yorukoglu K, Aslan G, et al
    Sextant Biopsy-Based Criteria for Clinically Insignificant Prostate Cancer Are Also Valid for the 12-Core Prostate Biopsy Scheme: A Multicenter Study of Urooncology Association, Turkey.
    Urol Int. 2021 May 5:1-9. doi: 10.1159/000513658.
    PubMed     Abstract available

    March 2021
  27. ZHANG Q, Huang J, Xie C, Wu T, et al
    Adjuvant Chemotherapy in High-Risk Prostate Cancer Patients after Primary Local Therapy: Recurrence, Metastasis, and Survival - A Meta-Analysis.
    Urol Int. 2021 Mar 30:1-8. doi: 10.1159/000513941.
    PubMed     Abstract available

    January 2021
  28. HERDEN J, Schwarte A, Boedefeld EA, Weissbach L, et al
    Active Surveillance for Incidental (cT1a/b) Prostate Cancer: Long-Term Outcomes of the Prospective Noninterventional HAROW Study.
    Urol Int. 2021 Jan 29:1-8. doi: 10.1159/000512893.
    PubMed     Abstract available

  29. VON LANDENBERG N, Hanske J, Noldus J, Roghmann F, et al
    Probability of Prostate Cancer Diagnosis following Negative Systematic and Targeted MRI: Transrectal Ultrasound Fusion Biopsy: A Real-Life Observational Study.
    Urol Int. 2021 Jan 26:1-7. doi: 10.1159/000513075.
    PubMed     Abstract available

  30. MAURER V, Stahlberg J, Schiffmann I, Marks P, et al
    Continence and Complication Rates of Artificial Urinary Sphincter Devices (AMS 800) for Parkinson and Stroke Patients with Incontinence after Prostate Surgery: Retrospective Analysis of a Prospective Database.
    Urol Int. 2021;105.
    PubMed     Abstract available

  31. SHEN Q, Zhou Z, Liu Z, Hu S, et al
    Clinical and Pathological Features of Prostatic Stromal Tumor of Uncertain Malignant Potential: A Retrospective Study of 23 Chinese Cases.
    Urol Int. 2021;105.
    PubMed     Abstract available

  32. GOSSLER C, May M, Breyer J, Stojanoski G, et al
    High BMI, Aggressive Tumours and Long Console Time Are Independent Predictive Factors for Symptomatic Lymphocele Formation after Robot-Assisted Radical Prostatectomy and Pelvic Lymph Node Dissection.
    Urol Int. 2021;105.
    PubMed     Abstract available

  33. XU B, Ma BL, Peng YJ, Zhang Q, et al
    Learning Curve of an Innovative "3-Port" Laparoscopic Radical Prostatectomy: A Single-Center Analysis from 2016 to 2019.
    Urol Int. 2021;105.
    PubMed     Abstract available

  34. SCHMITZ-DRAGER BJ, Muhlich S, Lange C, Benderska-Soder N, et al
    Effectiveness and Distribution of Testosterone Levels within First Year of Androgen Deprivation Therapy in a Real-World Setting: Results from the Non-Interventional German Cohort LEAN Study.
    Urol Int. 2021;105.
    PubMed     Abstract available

  35. APFELBECK M, Schlenker B, Chaloupka M, Stief CG, et al
    Multiparametric MRI Lesion Classified as Prostate Imaging-Reporting and Data System 5 but Histopathologically Described as Benign: A Case Report and Review of Literature.
    Urol Int. 2021;105.
    PubMed     Abstract available

  36. NAKANISHI Y, Ito M, Kataoka M, Ikuta S, et al
    Who Can Avoid Biopsy of Magnetic Resonance Imaging-Negative Lobes without Compromising Significant Cancer Detection among Men with Unilateral Magnetic Resonance Imaging-Positive Lobes?
    Urol Int. 2021;105.
    PubMed     Abstract available

  37. PRATSINIS M, Babst C, Langenauer J, Schmid HP, et al
    Qualitative Assessment of Medical Information on YouTube: A Multilingual Comparison of Common Urological Conditions.
    Urol Int. 2021;105.
    PubMed     Abstract available

  38. MASSANOVA M, Robertson S, Barone B, Dutto L, et al
    The Comparison of Imaging and Clinical Methods to Estimate Prostate Volume: A Single-Centre Retrospective Study.
    Urol Int. 2021;105.
    PubMed     Abstract available

    December 2020
  39. LIU S, Wang XY, Huang TB, Ma XX, et al
    Impact of Radiotherapy on Prognosis in Patients Diagnosed with Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis.
    Urol Int. 2020 Dec 10:1-10. doi: 10.1159/000508415.
    PubMed     Abstract available

    October 2020
  40. TAFURI A, Rizzetto R, Amigoni N, Sebben M, et al
    Predictors of Lymph Node Invasion in Patients with Clinically Localized Prostate Cancer Who Undergo Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: The Role of Obesity.
    Urol Int. 2020 Oct 15:1-8. doi: 10.1159/000510008.
    PubMed     Abstract available

    September 2020
  41. CHEN Y, Lan T
    Molecular Origin, Expression Regulation, and Biological Function of Androgen Receptor Splicing Variant 7 in Prostate Cancer.
    Urol Int. 2020 Sep 21:1-17. doi: 10.1159/000510124.
    PubMed     Abstract available

  42. BERGIUS S, Roine RP, Taari K, Sintonen H, et al
    Health-Related Quality of Life and Survival in Prostate Cancer Patients in a Real-World Setting.
    Urol Int. 2020 Sep 21:1-9. doi: 10.1159/000510319.
    PubMed     Abstract available

    August 2020
  43. FANG WY, Wang PF, Fan YC, Shih HJ, et al
    Clinical Experience of Steroid Switch from Prednisone to Dexamethasone in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate.
    Urol Int. 2020 Aug 13:1-6. doi: 10.1159/000509882.
    PubMed     Abstract available

  44. NESTLER T, Wittersheim M, Schaefer S, Hellmich M, et al
    Prediction of Radioresistant Prostate Cancer Based on Differentially Expressed Proteins.
    Urol Int. 2020 Aug 13:1-12. doi: 10.1159/000509447.
    PubMed     Abstract available

  45. CLEMENTS MB, Abdalla B, Culp SH, Costabile RA, et al
    Prostate Cancer Characteristics in the US Preventive Services Task Force Grade D Era: A Single-Center Study and Meta-Analysis.
    Urol Int. 2020 Aug 6:1-7. doi: 10.1159/000507656.
    PubMed     Abstract available

  46. CELEN S, Gultekin A, Ozlulerden Y, Mete A, et al
    Comparison of 68Ga-PSMA-I/T PET-CT and Multiparametric MRI for Locoregional Staging of Prostate Cancer Patients: A Pilot Study.
    Urol Int. 2020 Aug 4:1-8. doi: 10.1159/000509974.
    PubMed     Abstract available

    July 2020
  47. SAAR M, Linxweiler J, Borkowetz A, Fussek S, et al
    Current Role of Multiparametric MRI and MRI Targeted Biopsies for Prostate Cancer Diagnosis in Germany: A Nationwide Survey.
    Urol Int. 2020 Jul 8:1-10. doi: 10.1159/000508755.
    PubMed     Abstract available

    May 2020
  48. TAFURI A, Sebben M, Pirozzi M, Processali T, et al
    Association between Basal Total Testosterone Levels and Prostate Cancer D'Amico Risk Classes.
    Urol Int. 2020 May 27:1-8. doi: 10.1159/000506525.
    PubMed     Abstract available

  49. SAWAZAKI H, Kitamura Y, Yagi K, Arai Y, et al
    Impact of Androgen Deprivation Therapy on Non-Alcoholic Fatty Liver Disease in Patients with Prostate Cancer: A CT Evaluation.
    Urol Int. 2020 May 12:1-6. doi: 10.1159/000507351.
    PubMed     Abstract available

  50. WESTHOFF N, Ritter M, Maros M, Rassweiler-Seyfried MC, et al
    Prospective Feasibility Study of Single-Shot Antibiotic Prophylaxis in Transrectal Focal Ablation of Prostate Cancer.
    Urol Int. 2020 May 12:1-8. doi: 10.1159/000507123.
    PubMed     Abstract available

  51. HENNENLOTTER J, Neumann T, Perner S, Wagner V, et al
    Impact of Histopathological Prostate Inflammation on Urine-Based Prostate Cancer Prediction Using the Prostate Cancer Gene 3 Score.
    Urol Int. 2020 May 8:1-6. doi: 10.1159/000506885.
    PubMed     Abstract available

    April 2020
  52. KAMEL MG, Istanbuly S, Abd-Elhay FA, Mohamed MYF, et al
    Examined and Positive Lymph Node Counts Are Associated with Mortality in Prostate Cancer: A Population-Based Analysis.
    Urol Int. 2020 Apr 8:1-11. doi: 10.1159/000505410.
    PubMed     Abstract available

    January 2020
  53. SCHULZE A, Christoph F, Sachs M, Schroeder J, et al
    Use of the Prostate Health Index and Density in 3 Outpatient Centers to Avoid Unnecessary Prostate Biopsies.
    Urol Int. 2020;104.
    PubMed     Abstract available

  54. YANG B, Zhang F, Xiao C, Lu J, et al
    Impact of Preoperative Magnetic Resonance Imaging Anatomic Features on Urinary Continence Recovery after Laparoscopic Radical Prostatectomy.
    Urol Int. 2020;104.
    PubMed     Abstract available

  55. ERB HHH, Sparwasser P, Diehl T, Hemmerlein-Thomas M, et al
    AR-V7 Protein Expression in Circulating Tumour Cells Is Not Predictive of Treatment Response in mCRPC.
    Urol Int. 2020;104.
    PubMed     Abstract available

  56. MAXEINER A, Nest AM, Stephan C, Cash H, et al
    Additive Value of Transrectal Systematic Ventral Biopsies in Combination with Magnet Resonance Imaging/Ultrasound Fusion-Guided Biopsy in Patients with 3 or More Negative Prostate Biopsies.
    Urol Int. 2020;104.
    PubMed     Abstract available

  57. LIU Y, Xiao G, Zhou JW, Yang JK, et al
    Optimal Starting Age and Baseline Level for Repeat Tests: Economic Concerns of PSA Screening for Chinese Men - 10-Year Experience of a Single Center.
    Urol Int. 2020;104.
    PubMed     Abstract available

  58. PARK J, Yoo S, Cho MC, Jeong CW, et al
    Patients with Biopsy Gleason Score 3 + 4 Are Not Appropriate Candidates for Active Surveillance.
    Urol Int. 2020;104.
    PubMed     Abstract available

  59. BERG S, Hanske J, von Landenberg N, Noldus J, et al
    Institutional Adoption and Apprenticeship of Fusion Targeted Prostate Biopsy: Does Experience Affect the Cancer Detection Rate?
    Urol Int. 2020;104.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.